Question 1

What are the potential benefits of participating in this trial for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder clinical trial (NCT06319170). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the olanzapine extended release compare to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder clinical trial (NCT06319170). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I be aware of with these formulations?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder clinical trial (NCT06319170). Contact the study team or your healthcare provider for specific answers.

Question 4

What will my participation involve in terms of hospital stays and visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder clinical trial (NCT06319170). Contact the study team or your healthcare provider for specific answers.

Question 5

How long will I need to be in the study, and what will the schedule look like?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder clinical trial (NCT06319170). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any risks associated with the trial that I should consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder clinical trial (NCT06319170). Contact the study team or your healthcare provider for specific answers.

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

What this study is about

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

What this study is about